Ravi K Amaravadi
· MDUniversity of Pennsylvania · Rehabilitation Medicine
Active 1997–2025
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Ravi K Amaravadi, MD, is the Tara Miller Professor of Melanoma Research and Patient Care at the University of Pennsylvania's Perelman School of Medicine. He is an attending physician at the Hospital of the University of Pennsylvania and a member of the Abramson Cancer Center, the Institute of Translational Medicine and Therapeutics, and the University of Pennsylvania GI Center for Molecular Studies of Digestive and Liver Diseases. His research expertise includes autophagy, mechanisms of cell death, and developmental therapeutics, with a clinical focus on Phase I and Phase II clinical trials in melanoma. Dr. Amaravadi's work involves understanding and targeting cellular processes to develop novel therapeutic strategies for melanoma and other cancers, contributing significantly to translational research in oncology.
Research topics
- Biology
- Cell biology
- Internal medicine
- Medicine
- Immunology
- Biochemistry
- Cancer research
- Chemistry
- Genetics
- Oncology
Selected publications
Autophagy in major human diseases
The EMBO Journal · 2021-08-30 · 1541 citations
reviewOpen accessAutophagy is a core molecular pathway for the preservation of cellular and organismal homeostasis. Pharmacological and genetic interventions impairing autophagy responses promote or aggravate disease in a plethora of experimental models. Consistently, mutations in autophagy-related processes cause severe human pathologies. Here, we review and discuss preclinical data linking autophagy dysfunction to the pathogenesis of major human disorders including cancer as well as cardiovascular, neurodegene…
Immunity · 2020 · 1028 citations
SIRT1 is downregulated by autophagy in senescence and ageing
Nature Cell Biology · 2020 · 460 citations
Nature Communications · 2021 · 292 citations
Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aim to estimate the effects of hydroxychloroquine and chloroquine on survival in COVID-19 from all currently available RCT evidence, published and unpublished. We present a rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine or chloroquine treatment for any COV…
JNCI Journal of the National Cancer Institute · 2020 · 135 citations
BACKGROUND: Gut microbial diversity is associated with improved response to immune checkpoint inhibitors (ICI). Based on the known detrimental impact that antibiotics have on microbiome diversity, we hypothesized that antibiotic receipt prior to ICI would be associated with decreased survival. METHODS: Patients with stage III and IV melanoma treated with ICI between 2008 and 2019 were selected from an institutional database. A window of antibiotic receipt within 3 months prior to the first infus…
Recent grants
NIH · $686k · 2014
Targeting HSP70 for MelanomaTherapy
NIH · $69.3M · 2008–2025
Molecular mechanisms of BRAF inhibitor induced UPR and autophagy
NIH · $1.8M · 2015–2021
Frequent coauthors
- 315 shared
Lynn M. Schuchter
University of Pennsylvania
- 202 shared
Giorgos C. Karakousis
- 165 shared
Tara C. Mitchell
- 162 shared
Meenhard Herlyn
- 138 shared
Qin Liu
Nanjing Drum Tower Hospital
- 131 shared
Keith T. Flaherty
Massachusetts General Hospital
- 120 shared
Xiaowei Xu
The Wistar Institute
- 101 shared
Alexander C. Huang
University of Pennsylvania
Labs
Amaravadi LabPI
Awards & honors
- Tara Miller Professor of Melanoma Research and Patient Care
- Member, Abramson Cancer Center
- Member, Institute of Translational Medicine and Therapeutics
- Member, University of Pennsylvania GI Center for Molecular S…
- Co-Director, University of Pennsylvania/Wistar Institute SPO…
Similar researchers at University of Pennsylvania
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Ravi K Amaravadi
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup